熱門資訊> 正文

Spruce Biosciences GAAP每股收益为-6.68美元

2026-08-12 21:05

Spruce Biosciences(SPRB) 0

Spruce Biosciences press release (SPRB): Q2 GAAP EPS of -$6.68.
Cash and cash equivalents as of June 30, 2026 were $96.3 million, compared to $48.9 million as of December 31, 2025.
Spruce believes that its cash and cash equivalents as of June 30, 2026 will be sufficient to fund its planned operations and debt obligations into the second half of 2027.

More on Spruce Biosciences

Spruce Biosciences Possibly First In-MPS IIIB Class Enzyme Replacement Therapy
Seeking Alpha’s Quant Rating on Spruce Biosciences
Historical earnings data for Spruce Biosciences
Financial information for Spruce Biosciences

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。